Galectin Therapeutics (NASDAQ:GALT) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened

Key Points

• Galectin Therapeutics fell below its 200-day moving average of $3.22, trading as low as $2.91 and last at $2.97.
• Analyst views are mixed: one Buy, one Hold and one Sell, producing an overall Hold rating and an average price target of $11.
• The company reported a quarterly loss of $0.14 per share, missing analysts’ estimate of a $0.09 loss; analysts expect a full-year loss of $0.30 per share.

Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report)'s share price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.22 and traded as low as $2.91. Galectin Therapeutics shares last traded at $2.97, with a volume of 396,557 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Zacks Research raised Galectin Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Galectin Therapeutics in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Galectin Therapeutics currently has an average rating of "Hold" and an average target price of $11.00.

Galectin Therapeutics Trading Down 14.4%

The stock has a market capitalization of $195.60 million, a P/E ratio of -6.91 and a beta of 0.53. The stock's fifty day moving average price is $3.76 and its two-hundred day moving average price is $3.22.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.05). As a group, analysts expect that Galectin Therapeutics Inc. will post -0.30 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Argyle Capital Partners LLC bought a new position in Galectin Therapeutics during the 2nd quarter worth approximately $62,000. Archer Investment Corp purchased a new position in Galectin Therapeutics in the 2nd quarter worth approximately $81,000. Bank of America Corp DE lifted its position in Galectin Therapeutics by 114.9% in the first quarter. Bank of America Corp DE now owns 53,862 shares of the company's stock valued at $150,000 after purchasing an additional 28,799 shares during the last quarter. Sovran Advisors LLC lifted its position in Galectin Therapeutics by 14.1% in the first quarter. Sovran Advisors LLC now owns 257,830 shares of the company's stock valued at $719,000 after purchasing an additional 31,956 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in Galectin Therapeutics by 13.1% in the third quarter. Commonwealth Equity Services LLC now owns 460,296 shares of the company's stock valued at $1,786,000 after purchasing an additional 53,183 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company's stock.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune regulation. The company's research is aimed at treating serious chronic diseases in which galectin-3 may contribute to disease progression.

Its lead investigational product is belapectin, also known as GR-MD-02, a galectin-3 inhibitor being studied primarily for liver diseases, including nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), and related cirrhosis complications such as portal hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.